Tuberculosis ResearchPersonalised Lung-on-Chip Model Reveals the Earliest Stages of TB
Source:
The Francis Crick Institute
3 min Reading Time
From tuberculosis to lung cancer, a new personalised lung-on-chip model opens the door to studying respiratory diseases in a realistic human system for the first time.
Image of the lung-on-chip, with cell nuclei in blue, macrophage in magenta, endothelial cells in yellow and tight junctions between epithelial and endothelial cells in white.
(Source: Jakson Luk, Science Advances)
Researchers at the Francis Crick Institute and AlveoliX have developed the first human ‘lung-on-chip’ model using stem cells taken from only one person. These chips simulate breathing motions and lung disease in an individual, holding promise for testing treatments for infections like tuberculosis (TB) and delivering personalised medicine.
Air sacs in the lungs called alveoli are the essential site of gas exchange and also an important barrier against inhaled viruses and bacteria that cause respiratory diseases like flu or TB.
Researchers have been working to recreate the battle between human cells and bacteria in the lab by building a ‘lung-on-a-chip’: small units of human lung on a plastic chip containing tiny channels and compartments. In this case, they aimed to recreate air sacs to understand how they respond to infection.
Until now, these ‘lung-on-chip’ devices have been made of a mixture of patient-derived and commercially available cells, meaning they can’t fully replicate the lung function or disease progression of a single individual.
In a study published in Science Advances, the team at the Crick developed a new lung-on-chip model that contains only genetically identical cells derived from stem cells from a single donor.
Based on a protocol developed previously by the lab, the team produced type I and II alveolar epithelial cells and vascular endothelial cells from human-induced pluripotent stem cells, cells that can virtually become any cell in the body. These epithelial and endothelial cells are separately grown on the top and bottom of a very thin membrane in a device manufactured by biotechnology company AlveoliX to recreate an air sac barrier.
New Paths for TB Research Without Animal Models
To further simulate the human lung, AlveoliX has designed specialised machines to impose rhythmic three-dimensional stretching forces on the recreated air sac barrier, mimicking the motion of breathing. This stimulates the formation of microvilli, a key feature of alveolar epithelial cells to increase surface area for lung functions.
Next, the scientists added immune cells called macrophages into the chip, again produced from the stem cells of the same donor, before adding TB bacteria to simulate the early stages of the disease.
In the chips infected with TB, the team reported large macrophage clusters containing ‘necrotic cores’, a group of dead macrophages in the centre, surrounded by live macrophages. Eventually, five days after infection, the endothelial and epithelial cell barriers collapsed, showing that the air sac function had broken down.
Max Gutierrez, Principal Group Leader of the Host-Pathogen Interactions in Tuberculosis Laboratory at the Crick and senior author, said: “Given the increasing need for non-animal technologies, organ-on-chip approaches are becoming ever more important to recreate human systems, avoiding differences in lung anatomy, makeup of immune cells and disease development between animals and humans.
“Composed of entirely genetically identical cells, the chips could be built from stem cells from people with particular genetic mutations. This would allow us to understand how infections like TB will impact an individual and test the effectiveness of treatments like antibiotics.”
Jakson Luk, Postdoctoral Fellow in the Host-Pathogen Interactions in Tuberculosis Laboratory and first author, said: “TB is a slow-moving disease, with months between infection and the development of symptoms, so there’s an increasing need to understand what’s happening in the unseen early stages.
“We were successfully able to mimic these initial events in TB progression, giving a holistic picture of how different lung cells respond to infections. We’re excited that the new model could be applied to a huge range of research, such as other respiratory infections or lung cancer, and we’re now looking at refining the chip by incorporating other important cell types.”
Original Article: Autologous human iPSC-derived Alveolus-on-Chip reveals early pathological events of M. tuberculosis infection; Science Advances; DOI:10.1126/sciadv.aea9874
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.